Details for Patent: 11,253,474
✉ Email this page to a colleague
Which drugs does patent 11,253,474 protect, and when does it expire?
Patent 11,253,474 protects NORLIQVA and is included in one NDA.
Summary for Patent: 11,253,474
| Title: | Pharmaceutical solution of amlodipine |
| Abstract: | Disclosed herein is a liquid pharmaceutical formulation substantially free of water, comprising: (i) amlodipine or a pharmaceutically acceptable salt thereof, (ii) at least one pharmaceutically acceptable excipient, and (iii) a sufficient amount of a vehicle comprising glycerin. Also disclosed herein is a liquid pharmaceutical formulation substantially free of water and ethanol, comprising: (i) amlodipine or a pharmaceutically acceptable salt thereof, (ii) at least one pharmaceutically acceptable excipient, and (iii) a sufficient amount of a vehicle comprising glycerin. |
| Inventor(s): | Mandal; Jayanta Kumar (Ahmedabad, IN), Patel; Malay (Amedabad, IN), Nagar; Swati (Amreli, IN), DeHart; Michael Paul (Winterville, NC) |
| Assignee: | LIQMEDS WORLDWIDE LIMITED (Haynes, GB) |
| Application Number: | 17/183,553 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Formulation; |
Drugs Protected by US Patent 11,253,474
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cmp Dev Llc | NORLIQVA | amlodipine besylate | SOLUTION;ORAL | 214439-001 | Feb 24, 2022 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | NORLIQVA IS INDICATED FOR THE TREATMENT OF HYPERTENSION, TO LOWER BLOOD PRESSURE IN ADULTS AND CHILDREN 6 YEARS OF AGE AND OLDER | ⤷ Sign Up | |||
| Cmp Dev Llc | NORLIQVA | amlodipine besylate | SOLUTION;ORAL | 214439-001 | Feb 24, 2022 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | NORLIQVA IS INDICATED FOR THE SYMPTOMATIC TREATMENT OF CHRONIC STABLE ANGINA | ⤷ Sign Up | |||
| Cmp Dev Llc | NORLIQVA | amlodipine besylate | SOLUTION;ORAL | 214439-001 | Feb 24, 2022 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | Y | NORLIQVA IS INDICATED FOR THE TREATMENT OF CONFIRMED OR SUSPECTED VASOSPASTIC ANGINA | ⤷ Sign Up | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
